Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Large epidemiological trails shown that hypercholesterolemia is one of the main risk factor of ischemic heart disease (IHD). Correction of the hypercholesterolemia with GmGKoA reductase inhibitors (statins) essentially reduces IHD morbidity and mortality. The lower serum level of low density lipoprotein is - the lower risk of cardiovascular diseases and their complications are. Efficacy and safety of atorvastatin therapy in high doses is discussed in patients with IHD and dyslipidemia. Atorvastatin in high doses is more effective than standard therapy for prevention of cardiovascular complications. Atorvastatin is also effective in patients with recurrent cardiovascular events. Atorvastatin in high doses is safe and well tolerated. Serious side effects due to atorvastatin use (myopathy and rhabdomyolysis) are very rare. Generic atorvastatin 80 mg OD in ATLANTIC study was effective and safe. However efficacy and safety of other atorvastatin generics in dose of 80 mg OD is not well studied and it is necessary further studies.

About the Author

A. N. Meshkov
Russian Cardiology Research and Production Complex
Russian Federation
Tretya Cherepkovskaya ul. 15a, Moscow, 121552


1. Kannel W.B. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988; 62(16):1109-12.

2. Wilson P.W., D'Agostino R.B., Levy D. et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18):1837-47.

3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934):1383–9.

4. Sacks F.M., Pfeffer M.A., Moye L.A. et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335(14):1001-9.

5. Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279(20):1615- 22.

6. Сусеков А.В., Зубарева М.Ю., Деев А.Д. и др. Основные результаты Московского Исследования по Статинам (Moscow Statin Survey, MSS). Сердце 2006;5(6):324-8.

7. Шальнова С.А., Деев А.Д. Характеристика пациентов высокого риска. Результатыэпидемиологической части научно-образовательной программы ОСКАР. Кардиоваскулярная терапия и профилактика 2006;5(5):58-63.

8. Мареев В.Ю., Даниелян М. О. Крестор: Эффективность и Безопасность у больных ишемической болезнью сердца (дизайн и основные результатыисследования КЭБ). Сердце 2008;7(1):65-70.

9. Мареев В.Ю., Беленков Ю.Н., Оганов Р.Г., Барбик-Жагар Б. Аторвастатин в лечении пациентов с ишемической болезнью сердца и дислипидемией и высоким общим риском: оценка эффективности и безопасности. Дизайн и основные результаты исследования АТЛАНТИКА. Кардиология 2008;48(11):4-13.

10. Waters D.D., Guyton J.R., Herrington D.M. et al. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004;93(2):154–8

11. LaRosa J.C., Grundy S.M., Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35.

12. Pedersen T.R., Faergeman O., Kastelein J.J. et al.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study. JAMA 2005;294(19):2437-45.

13. Ray K.K., Cannon C.P., McCabe C.H. et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 tri￾al. J Am Coll Cardiol 2005;46(8):1405-10

14. Nissen S.E., Tuzcu E., Schoenhagen P. et al. for REVERSAL Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352(1):29-38.

15. LaRosa J.C., Deedwania P.C., Shepherd J. et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol 2010;105(3):283-7.

16. Tikkanen M.J., Szarek M., Fayyad R. et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol 2009;54(25);2353-7.

17. Davidson M.H., Robinson J.G. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49(17):1753–62.

18. Downs J.R., Clearfield D.O., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20):1615–22.

19. Davidson M.H. Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf 2002;1(3):207-12.

20. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370(9601):1781-90.

For citation:

Meshkov A.N. EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES. Rational Pharmacotherapy in Cardiology. 2010;6(2):197-200. (In Russ.)

Views: 373

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)